ARS Pharmaceuticals Inc
NASDAQ:SPRY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.68
17.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Cash Equivalents
ARS Pharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
Cash Equivalents
$71m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
ARS Pharmaceuticals Inc
Glance View
ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, California and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is developing neffy (previously referred to ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type 1 allergic reactions, including food, medications, and insect bites that could lead to anaphylaxis. The firm has designed and developed neffy to provide injection-like absorption of epinephrine, in a small nasal spray device.
See Also
What is ARS Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
71m
USD
Based on the financial report for Dec 31, 2023, ARS Pharmaceuticals Inc's Cash Equivalents amounts to 71m USD.
What is ARS Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
29%
Over the last year, the Cash Equivalents growth was -66%. The average annual Cash Equivalents growth rates for ARS Pharmaceuticals Inc have been -43% over the past three years , 29% over the past five years .
You don't have any saved screeners yet
